Figure 4.
Let-7a regulates IL6 expression during transformation
(A) Let-7a binding site in 3′UTR of IL6 with sequence complementarity and phylogenic conservation (yellow) of IL6 target sequence indicated.
(B) Luciferase assay using a reporter containing the 3′UTR of IL6 (wt or mutant in let-7a binding site) 24h after transfection with let-7a or a scrambled miR control.
(C) Physical interaction between let-7a and IL6 mRNA in the context of the RISC complex. IL6 RNA levels in HA-Ago1 immunoprecipitates in HEK-293 cells co-transfected with a plasmid expressing HA-Ago1 and let-7a or scrambled microRNA control.
(D) IL6 RNA levels after treatment for 24h with antisense-let-7a (100 nM) or Lin28B.
(E) Phosphorylation of STAT3-Y705 ELISA assay; mean ± SD) in untreated and TAM-treated (36h) cells in addition to treatment with increasing concentrations (50, 80, 100 nM) of let-7a and siRNA against Lin28B (80 nM).
(F) VEGF and IL6 production (ELISA assay; mean ± SD) in TAM-treated cells before and after transfection (100 nM) of the indicated let-7 microRNAs.
(G) Western blot analysis of RAS protein expression in 36h TAM-treated cells after let-7a (100 nM) overexpression; GAPDH levels were used as a loading control.
(H) IL6 production (ELISA assay during transformation after transfection with negative control siRNA or siRNA against Ras or let-7a (100 nM).
(I) Soft agar colony assay in TAM-treated cells after treatment with 2 μg/ml of monoclonal antibody against IL6 (Ab-IL6) and IgG isotype antibody (Ab-IgG) or siRNA negative control and siRNA against Ras (100 nM).